

Effectiveness of the BNT162b2 Covid-19 Vaccine against

New England Journal of Medicine

385, 187-189

DOI: [10.1056/nejmc2104974](https://doi.org/10.1056/nejmc2104974)

Citation Report

#	ARTICLE	IF	CITATIONS
1	What is Currently Known About the SARS-CoV2 Variants of Concern. <i>Journal of Epidemiology and Global Health</i> , 2021, 11, 257.	1.1	2
2	SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-Reactive IgG and Unequal Strain-Specific Neutralizing Antibodies in Naïve and Previously Infected Recipients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
18	Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?. <i>Diagnostics</i> , 2021, 11, 941.	1.3	45
23	Pfizer COVID vaccine protects against worrying coronavirus variants. <i>Nature</i> , 2021, 593, 325-326.	13.7	14
27	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	69
34	Human Vaccines & Immunotherapeutics: News. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3260-3261.	1.4	0
35	Global Trends and Correlates of COVID-19 Vaccination Hesitancy: Findings from the iCARE Study. <i>Vaccines</i> , 2021, 9, 661.	2.1	57
36	A reasoned approach towards administering COVID-19 vaccines to pregnant women. <i>Prenatal Diagnosis</i> , 2021, 41, 1018-1035.	1.1	9
37	The Immunopathobiology of SARS-CoV-2 Infection. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	9
39	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
41	Has SARS-CoV-2 reached peak fitness?. <i>Nature Medicine</i> , 2021, 27, 1323-1324.	15.2	21
42	Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out. <i>Vaccines</i> , 2021, 9, 697.	2.1	15
45	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 676314.	1.5	17
46	Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination. <i>Vaccines</i> , 2021, 9, 700.	2.1	29
48	Review of the early reports of the epidemiological characteristics of the B.1.1.7 variant of SARS-CoV-2 and its spread worldwide. <i>Osong Public Health and Research Perspectives</i> , 2021, 12, 139-148.	0.7	9
49	Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, , 1-11.	1.0	15
52	Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. <i>PLoS Pathogens</i> , 2021, 17, e1009634.	2.1	43
53	SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. <i>Viruses</i> , 2021, 13, 1211.	1.5	35

#	ARTICLE	IF	CITATIONS
55	Six months of COVID vaccines: what 1.7 billion doses have taught scientists. <i>Nature</i> , 2021, 594, 164-167.	13.7	61
57	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. <i>Nature</i> , 2021, 596, 273-275.	13.7	318
62	Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. <i>Nature Medicine</i> , 2021, 27, 1379-1384.	15.2	296
64	COVID-19 vaccines for children younger than 12 years: are we ready?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1614-1615.	4.6	26
66	EMJ COVID-19 monthly top five. <i>Emergency Medicine Journal</i> , 2021, 38, 558-560.	0.4	0
68	Comprehensive Understanding and Field Application of COVID-19 Vaccine. <i>Korean Journal of Medicine</i> , 2021, 96, 155-159.	0.1	8
71	CureVac COVID vaccine let-down spotlights mRNA design challenges. <i>Nature</i> , 2021, 594, 483-483.	13.7	47
72	Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province. <i>Vaccines</i> , 2021, 9, 628.	2.1	42
73	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
77	SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. <i>Frontiers in Immunology</i> , 2021, 12, 701501.	2.2	157
80	Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	84
82	The new context in which breakthrough infections might emerge. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, , .	0.2	0
83	Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts. <i>BMC Medicine</i> , 2021, 19, 162.	2.3	25
85	SARS-CoV-2 vaccine effectiveness trumps immunogenicity in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 4105.	2.6	3
86	Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. <i>Eurosurveillance</i> , 2021, 26, .	3.9	127
87	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021, 27, 1614-1621.	15.2	337
90	Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. <i>Reviews in Medical Virology</i> , 2022, 32, e2277.	3.9	57
91	Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. <i>Vaccines</i> , 2021, 9, 781.	2.1	28

#	ARTICLE	IF	CITATIONS
92	Immunoinformatics approach for multi-epitope vaccine design against structural proteins and ORF1a polyprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2021, 7, 22.	0.9	17
94	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. <i>Nature Medicine</i> , 2021, 27, 1525-1529.	15.2	363
95	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
97	The Spike of SARS-CoV-2: Uniqueness and Applications. <i>Frontiers in Immunology</i> , 2021, 12, 663912.	2.2	14
99	Analysis of Delayed Vaccination Regimens: A Mathematical Modeling Approach. <i>Epidemiologia</i> , 2021, 2, 271-293.	1.1	13
104	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67
105	The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. <i>Current Biology</i> , 2021, 31, R918-R929.	1.8	246
107	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
108	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis. <i>Clinical Infectious Diseases</i> , 2022, 74, 734-742.	2.9	88
110	SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting. <i>Annals of Internal Medicine</i> , 2021, 174, 1404-1408.	2.0	100
111	Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 185.	3.8	37
117	Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: a systematic review. <i>Wellcome Open Research</i> , 0, 6, 185.	0.9	17
118	Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19). <i>Frontiers in Medicine</i> , 2021, 8, 702066.	1.2	14
119	Grand Challenges in Molecular Medicine for Disease Prevention and Treatment Through Cyclical Innovation. <i>Frontiers in Molecular Medicine</i> , 2021, 1, .	0.6	2
120	Possible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses. <i>Microorganisms</i> , 2021, 9, 1479.	1.6	10
121	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. <i>Nature Reviews Immunology</i> , 2021, 21, 475-484.	10.6	434
122	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. <i>Npj Vaccines</i> , 2021, 6, 104.	2.9	241
124	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. <i>Npj Vaccines</i> , 2021, 6, 97.	2.9	175

#	ARTICLE	IF	CITATIONS
125	Which are the best coronavirus disease 2019 vaccines?. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1729-1732.	2.8	2
126	Does BCG provide long-term protection against SARS-CoV-2 infection? A caseâ€“control study in Quebec, Canada. <i>Vaccine</i> , 2021, 39, 7300-7307.	1.7	13
127	Immunity to SARSâ€“CoVâ€“2 induced by infection or vaccination. <i>Journal of Internal Medicine</i> , 2022, 291, 32-50.	2.7	97
128	Optimizing testing regimes for the detection of COVID-19 in children and older adults. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 999-1016.	1.5	14
129	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021, 385, 585-594.	13.9	2,411
131	Living with COVID-19: The road ahead. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 619-628.	0.2	8
132	SARS-CoV-2 Vaccines: Where Are We Now?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3535-3543.	2.0	36
133	An Outbreak of COVID-19 among mRNA-Vaccinated Nursing Home Residents. <i>Vaccines</i> , 2021, 9, 859.	2.1	13
136	Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From QuÃ©bec, Canada. <i>Clinical Infectious Diseases</i> , 2022, 75, e805-e813.	2.9	26
137	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
140	Southeast Asia is an emerging hotspot for COVID-19. <i>Nature Medicine</i> , 2021, 27, 1495-1496.	15.2	48
142	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
144	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus diseaseâ€“19 pandemic. <i>Environmental Microbiology</i> , 2022, 24, 2615-2629.	1.8	23
145	Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. <i>Frontiers in Microbiology</i> , 2021, 12, 637554.	1.5	8
146	Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNeâ€“short- And long-term Immune reSponSe evAluation in health Care workErs. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2966-2979.	1.4	18
148	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. <i>Nature Reviews Immunology</i> , 2021, 21, 626-636.	10.6	777
149	Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa. <i>Emerging Infectious Diseases</i> , 2021, 27, 2009-2016.	2.0	12
151	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. <i>Pathogens</i> , 2021, 10, 1030.	1.2	33

#	ARTICLE	IF	CITATIONS
154	Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). <i>Clinical Infectious Diseases</i> , 2022, 75, e1128-e1136.	2.9	323
155	Immunization Update 2021. <i>Pharmacy Today</i> , 2021, 27, 52-62.	0.0	0
157	Deep Fractional Max Pooling Neural Network for COVID-19 Recognition. <i>Frontiers in Public Health</i> , 2021, 9, 726144.	1.3	16
158	Severe acute respiratory syndrome (SARS) coronavirus-2 infection (COVID-19) in pregnancy – An overview. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 263, 106-116.	0.5	8
159	Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination. <i>Journal of Infection</i> , 2021, 83, 237-279.	1.7	41
160	Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 376-382.	0.3	30
162	Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters. <i>Frontiers in Microbiology</i> , 2021, 12, 722178.	1.5	5
164	Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19. <i>Pharmaceutics</i> , 2021, 13, 1260.	2.0	11
165	Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	15
166	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. <i>Exploration of Immunology</i> , 2021, , 199-225.	1.7	5
167	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. <i>Cell Reports</i> , 2021, 36, 109493.	2.9	46
168	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <i>In Vivo</i> in a Mouse Model in a Neutralization-Dependent Manner. <i>MBio</i> , 2021, 12, e0100221.	1.8	7
169	Opinion on the Policy of Lifting Restrictions to Entry Under the Circumstance of the COVID-19 Pandemic. <i>Infectious Diseases & Immunity</i> , 2021, Publish Ahead of Print, .	0.2	0
171	Global Trends in Ophthalmic Practices in Response to COVID-19. <i>Ophthalmology</i> , 2021, 128, 1505-1515.	2.5	7
172	SARS-CoV-2 Infection, COVID-19, and long covid: Saga of erratic immune response, waning immunity, and immune system failure. <i>Journal of Pulmonology and Respiratory Research</i> , 2021, 5, 078-087.	0.0	0
173	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
177	Herd immunity: challenges and the way forward in Korea. <i>Epidemiology and Health</i> , 2021, 43, e2021054.	0.8	4
179	Effectiveness of Pulmonary Rehabilitation in Severe and Critically Ill COVID-19 Patients: A Controlled Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8956.	1.2	19

#	ARTICLE	IF	CITATIONS
183	Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1110-1123.	1.9	26
184	COVID-19 Vaccine Hesitancy and Acceptance in a Cohort of Diverse New Zealanders. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 14, 100241.	1.3	40
186	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <i>Biomedicines</i> , 2021, 9, 1163.	1.4	18
187	Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. <i>International Journal of Infectious Diseases</i> , 2021, 112, 52-54.	1.5	59
188	Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir. <i>Biomedicines</i> , 2021, 9, 1230.	1.4	8
189	Tracking down B.1.351 SARS-CoV-2 variant in Pakistan through genomic surveillance. <i>Journal of Medical Virology</i> , 2022, 94, 32-34.	2.5	7
191	A closer look at U.S COVID-19 vaccination rates and the emergence of new SARS-CoV-2 variants: It's never late to do the right thing. <i>Annals of Medicine and Surgery</i> , 2021, 69, 102709.	0.5	4
192	A surrogate cell-based SARS-CoV-2 spike blocking assay. <i>European Journal of Immunology</i> , 2021, 51, 2665-2676.	1.6	3
193	Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy. <i>Dermatology and Therapy</i> , 2021, 11, 1889-1903.	1.4	6
195	COVID-19 Vaccines: Current Conditions and Future Prospects. <i>Biology</i> , 2021, 10, 960.	1.3	14
196	IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population. <i>Vaccines</i> , 2021, 9, 999.	2.1	23
197	COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies. <i>Microorganisms</i> , 2021, 9, 1964.	1.6	13
199	SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4687-4700.	2.5	26
202	From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. <i>Acta Biomaterialia</i> , 2021, 131, 16-40.	4.1	140
204	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	6.0	459
205	COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. <i>Cell</i> , 2021, 184, 5077-5081.	13.5	114
206	Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection. <i>Innate Immunity</i> , 2021, 27, 423-436.	1.1	6
207	Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm. <i>Frontiers in Immunology</i> , 2021, 12, 730051.	2.2	7

#	ARTICLE	IF	CITATIONS
209	Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations. JAMA - Journal of the American Medical Association, 2021, 326, 903.	3.8	29
210	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Science Translational Medicine, 2021, 13, eabj0847.	5.8	40
211	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. Vaccines, 2021, 9, 1017.	2.1	10
213	Vaccines for COVID-19: Where do we stand in 2021?. Paediatric Respiratory Reviews, 2021, 39, 22-31.	1.2	53
214	Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. New England Journal of Medicine, 2021, 385, e90.	13.9	209
215	E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. Infection, Genetics and Evolution, 2021, 93, 104941.	1.0	58
217	Wearing a mask does indeed matter: Lessons from the 2021 influenza infection season. European Journal of Internal Medicine, 2021, 91, 96-97.	1.0	0
218	Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. Vaccines, 2021, 9, 1052.	2.1	22
219	The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773.	7.7	778
220	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. Biomedicines, 2021, 9, 1303.	1.4	87
222	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. Briefings in Bioinformatics, 2022, 23, .	3.2	16
223	The Immune Response to SARS-CoV-2 and Variants of Concern. Viruses, 2021, 13, 1911.	1.5	18
228	Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States. Health Affairs, 2021, 40, 1465-1472.	2.5	84
229	SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study. BMJ Open Respiratory Research, 2021, 8, e001029.	1.2	22
230	Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK. Lancet Microbe, The, 2021, 2, e416-e418.	3.4	16
231	Prevention of host-to-host transmission by SARS-CoV-2 vaccines. Lancet Infectious Diseases, The, 2022, 22, e52-e58.	4.6	59
232	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. International Immunology, 2021, 33, 529-540.	1.8	28
234	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. Lancet Regional Health - Europe, The, 2021, 8, 100171.	3.0	70

#	ARTICLE	IF	CITATIONS
235	Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. <i>International Journal of Infectious Diseases</i> , 2021, 110, 353-358.	1.5	74
236	The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. <i>Public Health</i> , 2021, 198, 230-237.	1.4	70
237	Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5573.	5.8	36
238	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. <i>Immunity</i> , 2021, 54, 2893-2907.e5.	6.6	107
239	Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. <i>Microbiology Spectrum</i> , 2021, 9, e0034121.	1.2	114
240	Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines. <i>PLoS ONE</i> , 2021, 16, e0252849.	1.1	11
242	mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 393-395.	1.0	6
244	Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France. <i>The Lancet Healthy Longevity</i> , 2021, 2, e685-e687.	2.0	27
245	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	13.9	402
246	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773.	13.9	1,090
248	A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 111956.	2.5	13
249	COVID-19 vaccine strategies for Aotearoa New Zealand: a mathematical modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 15, 100256.	1.3	15
250	The Emergence of the New P.4 Lineage of SARS-CoV-2 With Spike L452R Mutation in Brazil. <i>Frontiers in Public Health</i> , 2021, 9, 745310.	1.3	8
251	Assessment of Simulated Surveillance Testing and Quarantine in a SARS-CoV-2 "Vaccinated Population of Students on a University Campus. <i>JAMA Health Forum</i> , 2021, 2, e213035.	1.0	4
252	Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population. <i>EClinicalMedicine</i> , 2021, 40, 101117.	3.2	25
253	Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 2673-2676.	2.0	40
254	Optimization and fine-tuning of DenseNet model for classification of COVID-19 cases in medical imaging. <i>International Journal of Information Management Data Insights</i> , 2021, 1, 100020.	6.5	30
255	Will vaccine-derived protective immunity curtail COVID-19 variants in the US?. <i>Infectious Disease Modelling</i> , 2021, 6, 1110-1134.	1.2	24

#	ARTICLE	IF	CITATIONS
259	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	1.1	12
260	Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e1188-e1191.	2.9	38
261	Infectiologie : vaccins contre la COVID-19. <i>Perfectionnement En Pédiatrie</i> , 2021, 4, S16-S18.	0.0	0
263	Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. <i>World Psychiatry</i> , 2022, 21, 124-132.	4.8	105
265	An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants. <i>Viruses</i> , 2021, 13, 2009.	1.5	9
266	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. <i>Npj Vaccines</i> , 2021, 6, 125.	2.9	17
267	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
268	COVID-19 Risk Assessment for the Tokyo Olympic Games. <i>Frontiers in Public Health</i> , 2021, 9, 730611.	1.3	9
269	mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. <i>ELife</i> , 2021, 10, .	2.8	63
270	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021, 600, 517-522.	13.7	239
271	Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. <i>Science Advances</i> , 2021, 7, eabj3627.	4.7	24
272	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. <i>Interface Focus</i> , 2021, 11, 20210008.	1.5	24
273	Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. <i>Lancet Regional Health - Europe</i> , The, 2021, 11, 100249.	3.0	115
274	COVID-19: State of the Vaccination. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 508-518.	0.3	5
275	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
276	Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans. <i>JAMA Network Open</i> , 2021, 4, e2128391.	2.8	44
277	SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	49
278	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38

#	ARTICLE	IF	CITATIONS
279	COVID-19 Case Fatality and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1447-1452.	1.2	17
280	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. <i>Current Molecular Medicine</i> , 2022, 22, 621-639.	0.6	2
281	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1450-1466.	5.2	110
282	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196.	2.1	15
283	The global transmission of new coronavirus variants. <i>Environmental Research</i> , 2022, 206, 112240.	3.7	48
284	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
285	Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. <i>Cell Reports Medicine</i> , 2021, 2, 100450.	3.3	17
287	Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 – May 2021. <i>PLoS ONE</i> , 2021, 16, e0258513.	1.1	37
288	Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers. <i>PLoS ONE</i> , 2021, 16, e0258820.	1.1	37
289	SARS-CoV-2 infection generates tissue-localized immunological memory in humans. <i>Science Immunology</i> , 2021, 6, eabl9105.	5.6	147
291	National survey on deceased donor organ transplantation during the COVID-19 pandemic in Japan. <i>Surgery Today</i> , 2022, 52, 763-773.	0.7	7
292	Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2021, 41, 837-850.	1.2	6
293	Facile Synthesis of N-Doped Graphene Quantum Dots as Novel Transfection Agents for mRNA and pDNA. <i>Nanomaterials</i> , 2021, 11, 2816.	1.9	11
294	Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. <i>Lancet</i> , 2021, 398, 1407-1416.	6.3	978
295	Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Diseases, 2022, 75, e774-e782.	2.9	5
296	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021, 385, e83.	13.9	675
297	Vaccine breakthrough infections in veterans hospitalized with coronavirus infectious disease-2019: A case series. <i>American Journal of Infection Control</i> , 2022, 50, 273-276.	1.1	6
298	Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex. <i>In Silico Pharmacology</i> , 2021, 9, 55.	1.8	12

#	ARTICLE	IF	CITATIONS
299	Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity. <i>Vaccines</i> , 2021, 9, 1168.	2.1	19
300	Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. <i>EBioMedicine</i> , 2021, 73, 103626.	2.7	43
301	A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100044.	0.4	2
302	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. <i>Life</i> , 2021, 11, 1152.	1.1	5
303	BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 38-44.	2.4	12
304	Safe Surgery During the COVID-19 Pandemic. <i>Current Obesity Reports</i> , 2022, 11, 203-214.	3.5	2
305	Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study. <i>The Lancet Regional Health Americas</i> , 2022, 5, 100085.	1.5	30
306	Cognitive Barriers to COVID-19 Vaccine Uptake Among Older Adults. <i>Frontiers in Medicine</i> , 2021, 8, 756275.	1.2	11
307	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
308	Waning Immunity after the BNT162b2 Vaccine in Israel. <i>New England Journal of Medicine</i> , 2021, 385, e85.	13.9	860
309	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1930.	3.8	140
310	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. <i>Medicinski Podmladak</i> , 2021, 72, 20-29.	0.2	3
311	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
312	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. <i>Scientific Reports</i> , 2021, 11, 21601.	1.6	20
313	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
314	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
316	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021, 27, 2136-2143.	15.2	346
317	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44

#	ARTICLE	IF	CITATIONS
318	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?. <i>Frontiers in Immunology</i> , 2021, 12, 797117.	2.2	4
319	The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 789427.	1.8	100
320	The impact of COVID-19 on global tuberculosis control. <i>Indian Journal of Medical Research</i> , 2021, 153, 404-408.	0.4	0
321	Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. <i>Infectious Diseases of Poverty</i> , 2021, 10, 132.	1.5	244
322	Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. <i>Frontiers in Immunology</i> , 2021, 12, 772240.	2.2	33
323	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. <i>Vaccines</i> , 2021, 9, 1345.	2.1	22
324	Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis. <i>PLoS ONE</i> , 2021, 16, e0258997.	1.1	10
325	Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. <i>Journal of Virology</i> , 2022, 96, JVI0197321.	1.5	35
326	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. <i>Nature Communications</i> , 2021, 12, 6871.	5.8	147
327	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. <i>Archives of Virology</i> , 2022, 167, 293-305.	0.9	28
328	Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 114, 252-260.	1.5	380
329	Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142.	2.9	26
330	VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants. <i>Vaccines</i> , 2021, 9, 1409.	2.1	22
331	Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections. <i>New England Journal of Medicine</i> , 2021, 385, 2487-2489.	13.9	132
332	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15
333	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
334	Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study. <i>Microbiology Spectrum</i> , 2021, 9, e0188221.	1.2	5
335	mRNA vaccines against COVID-19: a showcase for the importance of microbial biotechnology. <i>Microbial Biotechnology</i> , 2022, 15, 135-148.	2.0	9

#	ARTICLE	IF	CITATIONS
336	The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants. <i>Scientific Reports</i> , 2021, 11, 22970.	1.6	20
337	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
338	Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. <i>Global Epidemiology</i> , 2021, 3, 100068.	0.6	30
340	COVID-19 reinfection: the role of natural immunity, vaccines, and variants. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 733-739.	0.4	22
341	Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review. <i>Vaccines</i> , 2021, 9, 1305.	2.1	39
342	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study. <i>PLoS ONE</i> , 2021, 16, e0258704.	1.1	12
343	Opposing Mechanisms Involving Perceived Benefits versus Safety Partially Explained an Increase in COVID-19 Vaccination Intention among Unvaccinated Chinese Adults during a Post-Rollout Period: Results of Two Serial Surveys. <i>Vaccines</i> , 2021, 9, 1414.	2.1	5
344	SARS-CoV-2 variants of concern dominate in Lahore, Pakistan in April 2021. <i>Microbial Genomics</i> , 2021, 7, .	1.0	9
345	Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 398-404.	2.8	90
346	One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 768883.	1.8	56
347	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	13.5	72
348	Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas. <i>American Journal of Pathology</i> , 2022, 192, 320-331.	1.9	90
349	A Comparison of COVID-19 Stigma and AIDS Stigma During the COVID-19 Pandemic: A Cross-Sectional Study in China. <i>Frontiers in Psychiatry</i> , 2021, 12, 782501.	1.3	8
350	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study. <i>EClinicalMedicine</i> , 2021, 42, 101190.	3.2	22
352	Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine. <i>Cell Research</i> , 2022, 32, 107-109.	5.7	69
353	An Analysis of Conspiracy Beliefs of Covid-19 Vaccination in Ghana. <i>Advances in Journalism and Communication</i> , 2021, 09, 196-208.	0.1	2
354	OUP accepted manuscript. <i>Briefings in Bioinformatics</i> , 2022, , .	3.2	2
355	The impact of COVID-19 on global tuberculosis control. <i>Indian Journal of Medical Research</i> , 2021, 153, 404.	0.4	8

#	ARTICLE	IF	CITATIONS
356	Efficacy and effectiveness of COVID-19 vaccines: Progress and prospect. , 2021, 1, 17.		2
357	Evaluation of protection by COVID-19 vaccines after deployment in low and lower-middle income countries. EClinicalMedicine, 2022, 43, 101253.	3.2	10
359	Multilevel determinants of COVID-19 vaccination hesitancy in the United States: A rapid systematic review. Preventive Medicine Reports, 2022, 25, 101673.	0.8	71
360	The Impact of COVID-19 on Hospitality Travelers's Safety and the Quality of Life. SSRN Electronic Journal, 0, , .	0.4	0
361	County-Level Vaccination Coverage and Rates of COVID-19 Cases and Deaths in the United States. SSRN Electronic Journal, 0, , .	0.4	0
362	Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants. Clinical and Translational Medicine, 2021, 11, e644.	1.7	7
363	Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant. Science Advances, 2022, 8, eabm0300.	4.7	6
364	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. Nature Communications, 2022, 13, 532.	5.8	53
365	Great Expectations of COVID-19 Herd Immunity. MBio, 2022, 13, e0349521.	1.8	9
367	Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study. Frontiers in Public Health, 2021, 9, 801763.	1.3	9
368	Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerging Microbes and Infections, 2022, 11, 477-481.	3.0	104
371	Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut-Lung Axis: Future Possibilities for SARS-CoV-2 Protection. BioTech, 2022, 11, 3.	1.3	4
372	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity, 2022, 55, 355-365.e4.	6.6	76
373	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	7.1	9
374	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. Nano-Micro Letters, 2022, 14, 41.	14.4	26
376	Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production. BMC Medicine, 2022, 20, 29.	2.3	20
377	Covid-19 vaccines production and societal immunization under the serendipity-mindsponge-3D knowledge management theory and conceptual framework. Humanities and Social Sciences Communications, 2022, 9, .	1.3	85
379	Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI). Vaccine, 2022, 40, 512-520.	1.7	14

#	ARTICLE	IF	CITATIONS
380	A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States. <i>Viruses</i> , 2022, 14, 104.	1.5	1
381	Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review. <i>Vaccines</i> , 2022, 10, 82.	2.1	16
382	A systematic review of methodological approaches for evaluating real-world effectiveness of COVID-19 vaccines: Advising resource-constrained settings. <i>PLoS ONE</i> , 2022, 17, e0261930.	1.1	22
383	Effectiveness of Vaccination against SARS-CoV-2 Infection in the Pre-Delta Era: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 157.	2.1	10
385	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
386	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
387	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
390	Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. <i>Lancet, The</i> , 2022, 399, 25-35.	6.3	109
391	Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 812176.	2.2	10
392	Attitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland. <i>Vaccines</i> , 2022, 10, 68.	2.1	22
394	The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients. <i>Cureus</i> , 2022, 14, e21485.	0.2	10
395	Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection. <i>EMBO Molecular Medicine</i> , 2022, 14, e15227.	3.3	31
396	A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2. <i>Cell Reports</i> , 2022, 38, 110256.	2.9	19
397	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
398	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0262897.	1.1	1
399	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.1	0
400	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
401	SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. <i>Cell Reports</i> , 2022, 38, 110336.	2.9	41

#	ARTICLE	IF	CITATIONS
402	Identification of cytotoxic T cells and their T cell receptor sequences targeting COVID-19 using MHC class I-binding peptides. <i>Journal of Human Genetics</i> , 2022, 67, 411-419.	1.1	5
403	mRNA Covid-19 vaccines in pregnancy: A systematic review. <i>PLoS ONE</i> , 2022, 17, e0261350.	1.1	50
404	Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e878-e879.	2.9	20
405	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 373-385.	1.1	24
406	Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey. <i>Vaccine</i> , 2022, 40, 1829-1836.	1.7	7
407	Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study. <i>Infectious Diseases Now</i> , 2022, 52, 40-43.	0.7	5
408	County-level vaccination coverage and rates of COVID-19 cases and deaths in the United States: An ecological analysis. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100191.	1.5	13
409	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. <i>Annals of Medicine</i> , 2022, 54, 524-540.	1.5	225
410	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. <i>Cell</i> , 2022, 185, 896-915.e19.	13.5	189
411	Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. <i>JAMA Internal Medicine</i> , 2022, 182, 197.	2.6	81
412	Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. <i>Science</i> , 2022, 375, 678-680.	6.0	303
413	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
414	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	77
415	Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. <i>Nature Microbiology</i> , 2022, 7, 379-385.	5.9	194
416	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
417	Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. <i>Nature Medicine</i> , 2022, 28, 823-830.	15.2	26
418	Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants. <i>Advanced Science</i> , 2022, 9, e2105378.	5.6	12
419	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience. <i>Journal of Global Health</i> , 2022, 12, 05004.	1.2	7

#	ARTICLE	IF	CITATIONS
421	Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa. <i>IScience</i> , 2022, 25, 103880.	1.9	6
422	SARS-CoV-2â€“Specific Vaccine Candidates; the Contribution of Structural Vaccinology. <i>Vaccines</i> , 2022, 10, 236.	2.1	14
423	Real-World Effectiveness of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic Hemodialysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e617-e622.	2.9	10
424	Predictors of uncertainty and unwillingness to receive the COVID-19 booster vaccine: An observational study of 22,139 fully vaccinated adults in the UK. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100317.	3.0	70
425	The variants of SARSâ€“CoVâ€“2 and the challenges of vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 1366-1372.	2.5	29
426	Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. <i>Infection</i> , 2022, 50, 309-325.	2.3	112
427	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. <i>Nature</i> , 0, , .	13.7	72
428	The effect of COVID-19 vaccination in Italy and perspectives for living with the virus. <i>Nature Communications</i> , 2021, 12, 7272.	5.8	40
429	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. <i>Nature Reviews Immunology</i> , 2022, 22, 57-65.	10.6	217
430	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. <i>Nature</i> , 2022, 602, 676-681.	13.7	1,038
431	Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant. <i>New England Journal of Medicine</i> , 2021, 385, 2585-2586.	13.9	94
432	Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population. <i>Clinical Infectious Diseases</i> , 2022, 75, e849-e856.	2.9	23
433	Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	20
441	Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). <i>Science Advances</i> , 2021, 7, eabk0172.	4.7	32
442	Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants. <i>MBio</i> , 2021, 12, e0265621.	1.8	14
443	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003879.	3.9	54
444	The pigtail macaque (<i>Macaca nemestrina</i>) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease. <i>PLoS Pathogens</i> , 2021, 17, e1010162.	2.1	11
445	SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 777212.	1.8	29

#	ARTICLE	IF	CITATIONS
446	mRNA, a Revolution in Biomedicine. <i>Pharmaceutics</i> , 2021, 13, 2090.	2.0	26
447	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2021, , eabj5305.	5.8	4
448	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2021, , eabm3302.	5.8	13
449	Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies. <i>International Journal of Epidemiology</i> , 2022, 51, 1088-1105.	0.9	25
450	Natural Capital Exploration and Coronavirus Disease Spread in 2020. <i>Theoretical Economics Letters</i> , 2022, 12, 411-419.	0.2	0
451	ChAdOx1 nCoV-19, BNT162b2 and CoronaVac Vaccines Do Not Induce as Strong Neutralising Antibodies with Broad Variant Protection as Infection and Suggest Vaccines that Induce Broader Sterilising Immunity are Essential to Stop the Pandemic. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
452	Reactogenicity to COVID-19 vaccination in the United States of America. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 104.	1.1	6
453	Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 835830.	2.2	19
454	The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA. <i>Pharmaceutics</i> , 2022, 14, 460.	2.0	11
455	Durability and expansion of neutralizing antibody breadth following Ad26.COVS.2.S vaccination of mice. <i>Npj Vaccines</i> , 2022, 7, 23.	2.9	6
456	Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100198.	1.5	62
458	A COVID-19 vaccination model for Aotearoa New Zealand. <i>Scientific Reports</i> , 2022, 12, 2720.	1.6	25
459	COVID-19: vaccines, efficacy and effects on variants. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 180-191.	1.2	24
461	BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant. <i>Communications Medicine</i> , 2022, 2, .	1.9	18
464	High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens. <i>Microbiology Spectrum</i> , 2022, 10, e0169521.	1.2	8
465	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2040330.	1.4	5
466	A Correlation Study of COVID-19 in Europe Considering Different Vaccines, Age Groups and Variants Including Delta and Omicron. <i>BioMed</i> , 2022, 2, 133-169.	0.6	1
468	The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals. <i>Vaccine</i> , 2022, 40, 1928-1931.	1.7	5

#	ARTICLE	IF	CITATIONS
469	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. <i>Cell Reports</i> , 2022, 38, 110561.	2.9	16
470	Ô€œs Omicron mildÔ€? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies. <i>Journal of Medical Virology</i> , 2022, 94, 3521-3539.	2.5	20
471	Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. <i>Nature Communications</i> , 2022, 13, 1699.	5.8	34
472	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. <i>New England Journal of Medicine</i> , 2022, 386, 1532-1546.	13.9	1,709
473	æ–°âžžã,³ãfãfŠã, ã,ãf«ã,1æ,,ÿæÿ“ç–†ã€•æ²»ç™,æ^ ç•ÿããfã,ãfãf³ããã,ã ã€. Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaho, 2022,		
474	Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. <i>Frontiers in Immunology</i> , 2022, 13, 861050.	2.2	8
475	Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, 845887.	2.2	13
476	Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity. <i>Frontiers in Immunology</i> , 2022, 13, 830433.	2.2	12
477	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	4
478	SARS-CoV-2 receptor binding domain displayed on HBsAg virusâ€“like particles elicits protective immunity in macaques. <i>Science Advances</i> , 2022, 8, eabl6015.	4.7	27
479	Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination. <i>Microbiology Spectrum</i> , 2022, 10, e0225221.	1.2	9
480	Broad antiâ€“SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination. <i>Science</i> , 2022, 375, 1041-1047.	6.0	59
481	Assessment of the feasibility of pool testing for SARS-CoV-2 infection screening. <i>Infectious Diseases</i> , 2022, 54, 478-487.	1.4	1
482	COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1) Tj ETQq1 1 0.784314 rgBT /Overbo	2.1	9
483	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
484	SARS-CoV-2 variants, immune escape, and countermeasures. <i>Frontiers of Medicine</i> , 2022, 16, 196-207.	1.5	39
487	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1804-1816.	13.9	311
488	Decoupling of omicron variant infections and severe COVID-19. <i>Lancet</i> , The, 2022, 399, 1047-1048.	6.3	22

#	ARTICLE	IF	CITATIONS
489	Human Amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation. <i>Stem Cell Research and Therapy</i> , 2022, 13, 126.	2.4	15
490	Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population. <i>Clinical Infectious Diseases</i> , 2022, 75, e579-e584.	2.9	17
491	Estimation of Real-World Vaccination Effectiveness of mRNA COVID-19 Vaccines against Delta and Omicron Variants in Japan. <i>Vaccines</i> , 2022, 10, 430.	2.1	22
492	A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. <i>AAPS PharmSciTech</i> , 2022, 23, 95.	1.5	3
493	Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. <i>RNA Biology</i> , 2022, 19, 386-410.	1.5	19
494	Global landscape of SARS-CoV-2 genomic surveillance and data sharing. <i>Nature Genetics</i> , 2022, 54, 499-507.	9.4	138
496	Vaccines Against COVID-19: A Review. <i>Vaccines</i> , 2022, 10, 414.	2.1	8
497	Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study. <i>Frontiers in Medicine</i> , 2022, 9, 828402.	1.2	5
498	To disclose or not to disclose? Factors related to the willingness to disclose information to a COVID-19 tracing app. <i>Information, Communication and Society</i> , 2023, 26, 1954-1978.	2.6	8
499	Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. <i>JAMA Oncology</i> , 2022, 8, 748.	3.4	20
500	Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study. <i>Vaccines</i> , 2022, 10, 479.	2.1	9
501	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. <i>Vaccine</i> , 2022, 40, 1483-1492.	1.7	32
502	A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. <i>Scientific Reports</i> , 2022, 12, 3884.	1.6	11
503	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	7
504	Viral Load Among Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Persons Infected With the SARS-CoV-2 Delta Variant. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac135.	0.4	40
505	Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents. <i>JAMA Network Open</i> , 2022, 5, e220935.	2.8	20
506	Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. <i>Journal of Personalized Medicine</i> , 2022, 12, 386.	1.1	5
507	Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study. <i>Annals of Neurology</i> , 2022, 91, 782-795.	2.8	22

#	ARTICLE	IF	CITATIONS
509	Boosters reduce in-hospital mortality in patients with COVID-19: An observational cohort analysis. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100227.	1.5	8
510	Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients. <i>Clinical Immunology</i> , 2022, 238, 108999.	1.4	10
511	The Need for Pre-vaccination Screening. <i>International Journal of Infection</i> , 2022, In Press, .	0.4	0
512	Modeling COVID-19 dynamic using a two-strain model with vaccination. <i>Chaos, Solitons and Fractals</i> , 2022, 157, 111927.	2.5	26
514	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41.	2.9	4
515	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 “a review. <i>Translational Research</i> , 2022, 242, 1-19.	2.2	3
516	SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 499-502.	1.0	10
517	Adherence to COVID-19 preventive measures and its association with intimate partner violence among women in informal settings of Kampala, Uganda. <i>PLOS Global Public Health</i> , 2022, 2, e0000177.	0.5	5
519	mRNA vaccines for COVID-19 and diverse diseases. <i>Journal of Controlled Release</i> , 2022, 345, 314-333.	4.8	50
520	Explaining higher Covid-19 vaccination among some US primary care professionals. <i>Social Science and Medicine</i> , 2022, 301, 114935.	1.8	9
521	Modelling the COVID-19 epidemic and the vaccination campaign in Italy by the SUIHTER model. <i>Infectious Disease Modelling</i> , 2022, 7, 45-63.	1.2	11
522	SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105151.	1.6	11
523	Immunotherapy for neuroblastoma using mRNA vaccines. <i>Advances in Cancer Biology Metastasis</i> , 2022, 4, 100033.	1.1	3
524	Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period. <i>International Immunopharmacology</i> , 2022, 108, 108766.	1.7	12
526	Pases sanitarios para COVID-19. <i>Cuadernos Filosóficos / Segunda Época</i> , 2021, , .	0.0	0
527	Effectiveness of BNT162b2 and ChAdOx1 Vaccines against Symptomatic COVID-19 among Healthcare Workers in Kuwait: A Retrospective Cohort Study. <i>Healthcare (Switzerland)</i> , 2021, 9, 1692.	1.0	6
529	mRNA Vaccines. , 2021, , .		0
531	Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2021, 9, e0165921.	1.2	2

#	ARTICLE	IF	CITATIONS
535	COVID-19 Seroprevalence in Canada Modelling Waning and Boosting COVID-19 Immunity in Canada a Canadian Immunization Research Network Study. <i>Vaccines</i> , 2022, 10, 17.	2.1	16
536	Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure. <i>PLoS ONE</i> , 2021, 16, e0260438.	1.1	6
537	Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis. <i>Clinical and Molecular Allergy</i> , 2021, 19, 25.	0.8	1
538	Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021. <i>Vaccines</i> , 2021, 9, 1489.	2.1	18
540	A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. <i>Nature Communications</i> , 2021, 12, 7105.	5.8	22
541	Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. <i>PLoS Biology</i> , 2021, 19, e3001384.	2.6	15
542	COVID-19 Vaccination in Children: An Open Question. <i>Current Pediatric Reviews</i> , 2022, 18, 226-236.	0.4	5
543	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 1601-1614.	0.9	8
548	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. <i>Cell Transplantation</i> , 2022, 31, 096368972210902.	1.2	3
549	Which vaccination strategy against COVID-19?. <i>International Health</i> , 2023, 15, 150-160.	0.8	0
550	A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. <i>Frontiers in Immunology</i> , 2022, 13, 857440.	2.2	15
551	Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. <i>Scientific Reports</i> , 2022, 12, 6241.	1.6	12
552	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
553	Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers. <i>Vaccine</i> , 2022, 40, 2915-2924.	1.7	5
554	Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. , 2022, 1, .		5
555	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. <i>Vaccines</i> , 2022, 10, 591.	2.1	27
556	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	62
557	Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e361-e367.	2.9	83

#	ARTICLE	IF	CITATIONS
558	Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission. <i>Epidemics</i> , 2022, 39, 100567.	1.5	2
559	The need for linked genomic surveillance of SARS-CoV-2. <i>Canada Communicable Disease Report</i> , 2022, 48, 131-139.	0.6	13
560	Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron. <i>Journal of Infectious Diseases</i> , 2022, 226, 1551-1555.	1.9	4
561	COVID-19 Vaccination and Estimated Public Health Impact in California. <i>JAMA Network Open</i> , 2022, 5, e228526.	2.8	15
562	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
563	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. <i>Science Translational Medicine</i> , 2021, , eabj6824.	5.8	11
564	Relationship between blood clots and COVID-19 vaccines: A literature review. <i>Open Life Sciences</i> , 2022, 17, 401-415.	0.6	6
566	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
567	The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. <i>Viruses</i> , 2022, 14, 854.	1.5	5
568	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. <i>Frontiers in Immunology</i> , 2022, 13, 804945.	2.2	12
569	Variant-specific vaccination induces systems immune responses and potent inÂvivo protection against SARS-CoV-2. <i>Cell Reports Medicine</i> , 2022, 3, 100634.	3.3	10
570	Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. <i>Vaccines</i> , 2022, 10, 662.	2.1	17
571	A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 702.	2.1	18
572	Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19. <i>MBio</i> , 2022, 13, e0018122.	1.8	20
573	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 2022, 13, 814365.	2.2	10
574	Neutralizing Effect of Synthetic Peptides toward SARS-CoV-2. <i>ACS Omega</i> , 2022, 7, 16222-16234.	1.6	7
575	RETROSPECTIVE STUDY TO CORRELATE THE HRCT LUNG CHANGES IN RTPCR POSITIVE PATIENTS WITH VACCINATION STATUS. , 2022, , 64-65.		0
576	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77

#	ARTICLE	IF	CITATIONS
577	Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. <i>Med</i> , 2022, 3, 406-421.e4.	2.2	17
578	Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, 2161-2168.	2.9	35
579	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
580	Patterns of compliance with COVID-19 preventive measures among the public in Qatar and Kuwait. <i>Global Social Policy</i> , 2022, 22, 580-603.	1.0	1
581	Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection. <i>Science Immunology</i> , 2022, 7, eabq3511.	5.6	82
583	The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants. <i>Scientific Reports</i> , 2022, 12, 7493.	1.6	8
584	Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. <i>Cell Reports</i> , 2022, 39, 110862.	2.9	9
585	The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
586	Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. <i>Nature Immunology</i> , 2022, 23, 940-946.	7.0	67
587	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
588	Vaccines for Covid-19: An insight on their effectiveness and adverse effects. <i>Journal of Medical Virology</i> , 2022, , .	2.5	7
589	Robust models of disease heterogeneity and control, with application to the SARS-CoV-2 epidemic. <i>PLOS Global Public Health</i> , 2022, 2, e0000412.	0.5	0
590	Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1. <i>Science Immunology</i> , 2022, 7, eabo3425.	5.6	28
591	Effectiveness of Coronavirus Disease 2019 Vaccines in Preventing Infection, Hospital Admission, and Death: A Historical Cohort Study Using Iranian Registration Data During Vaccination Program. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	16
593	Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e35311.	1.2	13
594	Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review. <i>Infectious Diseases of Poverty</i> , 2022, 11, 53.	1.5	25
595	Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. <i>International Journal of Medical Sciences</i> , 2022, 19, 834-841.	1.1	4
596	Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine. <i>Science Bulletin</i> , 2022, 67, 1326-1330.	4.3	3

#	ARTICLE	IF	CITATIONS
597	SARS-CoV-2 in silico binding affinity to human leukocyte antigen (HLA) Class II molecules predicts vaccine effectiveness across variants of concern (VOC). <i>Scientific Reports</i> , 2022, 12, 8074.	1.6	5
598	Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges. <i>Pharmaceutics</i> , 2022, 14, 1066.	2.0	11
599	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003991.	3.9	75
600	Identifying as someone who avoids virus transmission strengthens physical distancing habit–behaviour relationships: A longitudinal multi–national study during the COVID–19 pandemic. <i>Applied Psychology: Health and Well-Being</i> , 2022, 14, 1464-1482.	1.6	2
601	Safety & effectiveness of COVID-19 vaccines: A narrative review. <i>Indian Journal of Medical Research</i> , 2022, 155, 91.	0.4	22
602	Clinical and Laboratory Differences Between Delta and UK Variants of SARS-CoV-2: B.1.617.2 and B.1.1.7. <i>Tohoku Journal of Experimental Medicine</i> , 2022, , .	0.5	2
603	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. , 0, , .		1
604	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	37
605	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	43
606	Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1391-1414.	1.8	8
607	Three-Dose Vaccination-Induced Immune Responses Protect Against SARS-CoV-2 Omicron BA.2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
609	Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. <i>BMJ, The</i> , 0, , e071113.	3.0	62
610	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. <i>Medical Review</i> , 2022, 2, 169-196.	0.3	5
611	Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. <i>BMJ, The</i> , 0, , e069989.	3.0	78
612	Changing Dynamics of SARS-CoV-2: A Global Challenge. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5546.	1.3	3
613	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
614	Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. <i>Cell Reports</i> , 2022, 39, 110924.	2.9	20
615	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149

#	ARTICLE	IF	CITATIONS
617	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
618	Luminescent Assay for the Screening of SARS-CoV-2 M ^{Pro} Inhibitors. <i>ChemBioChem</i> , 2022, 23, .	1.3	5
619	Mapping of SARS-CoV-2 spike protein evolution during the first and second waves of COVID-19 infections in India. <i>Future Virology</i> , 2022, 17, 557-575.	0.9	2
620	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. <i>Nature Immunology</i> , 2022, 23, 960-970.	7.0	39
621	COVID-19 waves: variant dynamics and control. <i>Scientific Reports</i> , 2022, 12, .	1.6	33
622	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, .	5.8	188
623	Diagnosis and prognosis of COVID-19 employing analysis of patients' plasma and serum via LC-MS and machine learning. <i>Computers in Biology and Medicine</i> , 2022, 146, 105659.	3.9	12
624	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
625	Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review. <i>Vaccines</i> , 2022, 10, 909.	2.1	6
626	Household Secondary Transmission of the Severe Acute Respiratory Syndrome Coronavirus 2 Alpha Variant From a Community Cluster in a Nursery in Japan. <i>Pediatric Infectious Disease Journal</i> , 0, Publish Ahead of Print, .	1.1	1
627	SARS-CoV-2: A Master of Immune Evasion. <i>Biomedicines</i> , 2022, 10, 1339.	1.4	24
628	Application of human RNase P normalization for the realistic estimation of SARS-CoV-2 viral load in wastewater: A perspective from Qatar wastewater surveillance. <i>Environmental Technology and Innovation</i> , 2022, 27, 102775.	3.0	17
629	Understanding determinants of COVID-19 vaccine hesitancy; an emphasis on the role of religious affiliation and individual's reliance on traditional remedy. <i>BMC Public Health</i> , 2022, 22, .	1.2	10
630	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. <i>Nature Medicine</i> , 2022, 28, 1715-1722.	15.2	29
631	COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 905.	2.1	5
632	Systemic Neutralizing Antibodies and Local Immune Responses Are Critical for the Control of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1262.	1.5	1
633	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> , 2022, 387, 21-34.	13.9	368
634	Personality and Motivation to Comply With COVID-19 Protective Measures in Germany. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	4

#	ARTICLE	IF	CITATIONS
635	SARS-CoV-2: phenotype, genotype, and characterization of different variants. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	12
637	COVID-19 Vaccines: Update of the vaccines in use and under development. Vacunas, 2022, , .	1.1	6
638	Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nature Communications, 2022, 13, .	5.8	104
639	Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in [®] , in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. EClinicalMedicine, 2022, 50, 101526.	3.2	20
641	A Review on Variant of Concern (Delta Variant of COVID 19). Asian Journal of Research in Pharmaceutical Science, 2022, , 146-150.	0.1	1
642	Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2049-2055.	0.5	7
643	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	59
644	Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March–April 2021. Clinical Infectious Diseases, 2022, 75, S155-S158.	2.9	3
645	Prevalence and correlates of COVID-19 vaccine hesitancy among the elderly in Qatar: A cross-sectional study. Medicine (United States), 2022, 101, e29741.	0.4	4
646	Comparison of clinical characteristics and outcomes of hospitalized patients with seasonal coronavirus infection and COVID-19: a retrospective cohort study. BMC Infectious Diseases, 2022, 22, .	1.3	1
647	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. Emerging Microbes and Infections, 2022, 11, 1890-1899.	3.0	12
648	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. International Journal of Molecular Sciences, 2022, 23, 7675.	1.8	9
649	SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model. Vaccines, 2022, 10, 1104.	2.1	4
652	The Real-World Impact of Vaccination on COVID-19 Cases During Europe's Fourth Wave. International Journal of Public Health, 0, 67, .	1.0	1
653	Advances in COVID-19 Vaccines and New Coronavirus Variants. Frontiers in Medicine, 0, 9, .	1.2	4
654	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure. , 0, , .		0
655	The kinetics of IgG subclasses and contributions to neutralizing activity against SARS-CoV-2 wild-type strain and variants in healthy adults immunized with inactivated vaccine. Immunology, 2022, 167, 221-232.	2.0	10
656	COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar. Journal of Global Health, 0, 12, .	1.2	48

#	ARTICLE	IF	CITATIONS
657	COVID-19: Challenges of Viral Variants. Annual Review of Medicine, 2023, 74, 31-53.	5.0	43
658	Hospitalization Outcomes Among Patients With COVID-19 Undergoing Remote Monitoring. JAMA Network Open, 2022, 5, e2221050.	2.8	11
659	<scp>COVID</scp> and plasma cells: Is there long-lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
661	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. International Immunology, 2022, 34, 595-607.	1.8	19
662	Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: A cohort study of 28 million people in France. Lancet Regional Health - Europe, The, 2022, 19, 100441.	3.0	13
663	Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study. The Lancet Regional Health Americas, 2022, 12, 100296.	1.5	5
664	Coronaviruses. , 2023, , 277-306.		0
665	Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo. Advanced Science, 2022, 9, .	5.6	9
666	Classifying COVID-19 Variants Based on Genetic Sequences Using Deep Learning Models. Springer Series in Reliability Engineering, 2023, , 347-360.	0.3	3
667	SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children. Science Translational Medicine, 2022, 14, .	5.8	32
668	SARS-CoV-2's Variants of Concern: A Brief Characterization. Frontiers in Immunology, 0, 13, .	2.2	31
669	Path to normality: Assessing the level of social-distancing measures relaxation against antibody-resistant SARS-CoV-2 variants in a partially-vaccinated population. Computational and Structural Biotechnology Journal, 2022, 20, 4052-4059.	1.9	5
670	Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. International Journal of Biological Sciences, 2022, 18, 4629-4641.	2.6	24
671	Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. International Journal of Biological Sciences, 2022, 18, 4642-4647.	2.6	4
672	Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	5
673	Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview. Journal of Diabetes and Metabolic Disorders, 2022, 21, 1763-1783.	0.8	4
676	Critical policies disparity of the first and second waves of COVID-19 in the United Kingdom. International Journal for Equity in Health, 2022, 21, .	1.5	3
677	COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron). ELife, 0, 11, .	2.8	36

#	ARTICLE	IF	CITATIONS
679	Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. <i>Nature Communications</i> , 2022, 13, .	5.8	33
680	Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination. <i>Vaccine</i> , 2022, , .	1.7	1
681	Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long-term care facility residents. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	3
682	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
683	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. <i>Nature Communications</i> , 2022, 13, .	5.8	49
685	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	1.8	47
686	Global Predictors of COVID-19 Vaccine Hesitancy: A Systematic Review. <i>Vaccines</i> , 2022, 10, 1349.	2.1	54
687	Characteristics and Vaccines: Five Variants of Concern of SARS-CoV-2. , 0, 8, 630-634.		0
688	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
689	Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks. <i>Expert Review of Vaccines</i> , 2022, 21, 1377-1394.	2.0	8
691	Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan. <i>Clinical Drug Investigation</i> , 2022, 42, 813-827.	1.1	12
693	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. <i>IScience</i> , 2022, 25, 104886.	1.9	5
694	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
695	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
696	Investigating the COVID-19 vaccine discussions on Twitter through a multilayer network-based approach. <i>Information Processing and Management</i> , 2022, 59, 103095.	5.4	23
697	Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?. <i>International Journal of Infectious Diseases</i> , 2022, 124, 1-10.	1.5	12
698	Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. , 2022, , 161-181.		0
699	Immune system diversity against SARS-CoV-2 infection and vaccines. , 2022, 1, 153.		0

#	ARTICLE	IF	CITATIONS
700	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
701	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
702	Timeline of Oxygen Demand in Patients with COVID-19 Pneumonia. <i>Internal Medicine</i> , 2023, , .	0.3	0
703	SARS-CoV-2 Infections in Vaccinated and Unvaccinated Populations in Camp Lemonnier, Djibouti, from April 2020 to January 2022. <i>Viruses</i> , 2022, 14, 1918.	1.5	0
704	Transition of Antibody Titers after SARS-CoV-2 mRNA Vaccination in Japanese Healthcare Workers. <i>Japanese Journal of Infectious Diseases</i> , 2023, 76, 72-76.	0.5	4
705	Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants. <i>PLoS Computational Biology</i> , 2022, 18, e1010563.	1.5	4
706	Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
707	Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System. <i>PLoS ONE</i> , 2022, 17, e0274309.	1.1	7
708	Duration of immune protection of SARS-CoV-2 natural infection against reinfection. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	54
709	Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation. <i>Vaccine</i> , 2022, , .	1.7	3
711	Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. <i>Emerging Microbes and Infections</i> , 2022, 11, 2412-2422.	3.0	10
712	SARS-CoV-2 Variant Surveillance in Genomic Medicine Era. <i>Infectious Diseases</i> , 0, , .	4.0	0
713	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	0.5	0
714	Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	1
715	Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	5
716	Vaccine Effectiveness against SARS-CoV-2 Variants in Adolescents from 15 to 90 Days after Second Dose: A Population-Based Test-Negative Case-Control Study. <i>Journal of Pediatrics</i> , 2023, 253, 189-196.e2.	0.9	5
717	Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment. <i>Applied Mathematical Modelling</i> , 2023, 114, 447-465.	2.2	23
718	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64

#	ARTICLE	IF	CITATIONS
719	The Recent Updates on Neoteric Variants of Covid-19 Virus and Therapeutic Effectiveness of Vaccines against the Variants.. Biomedical and Pharmacology Journal, 2022, 15, 1201-1211.	0.2	1
720	Insight into Delta variant dominated second wave of COVID-19 in Nepal. Epidemics, 2022, 41, 100642.	1.5	7
721	First Case of COVID-19 N501Y Variant of Concern Infection in a Patient with Chronic HIV Infection. Canadian Journal of General Internal Medicine, 2021, 16, .	0.6	0
722	Control Strategies for the COVID-19 Infection Wave in India: A Mathematical Model Incorporating Vaccine Effectiveness. IEEE Transactions on Computational Social Systems, 2022, , 1-11.	3.2	1
723	New approaches related to the use of polyamine-free and polyamine-deficient diets in the list of nutritional products for COVID-19 patients. , 0, , 14-24.		3
724	Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study. , 2022, 1, e000104.		12
725	Importancia de la vigilancia genómica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19. Revista De La Universidad Industrial De Santander Salud, 2022, 54, .	0.0	0
726	Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. Frontiers in Immunology, 0, 13, .	2.2	5
727	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vaccines, 2022, 10, 1751.	2.1	10
729	The effect of vaccination beliefs regarding vaccination benefits and COVID-19 fear on the number of vaccination injections. Frontiers in Psychology, 0, 13, .	1.1	3
730	Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. PLoS ONE, 2022, 17, e0263861.	1.1	12
732	SARS-CoV-2 variants of concern: a review. Monaldi Archives for Chest Disease, 0, , .	0.3	4
733	SARS-CoV-2 Variant-Specific Infectivity and Immune Profiles Are Detectable in a Humanized Lung Mouse Model. Viruses, 2022, 14, 2272.	1.5	3
734	Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine. Current Medical Research and Opinion, 2022, 38, 2069-2075.	0.9	1
735	Production and Purification of LTB-RBD: A Potential Antigen for Mucosal Vaccine Development against SARS-CoV-2. Vaccines, 2022, 10, 1759.	2.1	5
736	Two Ligand-Binding Sites on SARS-CoV-2 Non-Structural Protein 1 Revealed by Fragment-Based X-ray Screening. International Journal of Molecular Sciences, 2022, 23, 12448.	1.8	9
737	Parents' willingness to vaccinate themselves and their children with the booster vaccine against SARS-CoV-2: A cross-sectional study in Puyang city, China. Journal of Medical Virology, 2023, 95, .	2.5	7
738	Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants. Frontiers in Immunology, 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
739	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
740	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
741	Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 10-18.	0.6	5
743	Clinical characteristics of pediatric cases infected with the SARS-CoV-2 Omicron variant in a tertiary children's medical center in Shanghai, China. <i>World Journal of Pediatrics</i> , 2023, 19, 87-95.	0.8	7
744	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. <i>Infectious Diseases</i> , 0, , .	4.0	0
745	Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 30, 465-476.	2.3	6
746	Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
747	Geographic and Socioeconomic Inequalities in Delays in COVID-19 Vaccinations: A Cross-Sectional Study in Indonesia. <i>Vaccines</i> , 2022, 10, 1857.	2.1	6
748	Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses. <i>Archives of Medical Research</i> , 2022, 53, 694-710.	1.5	5
750	Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination. <i>IScience</i> , 2022, 25, 105379.	1.9	4
752	Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
753	Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population. <i>IScience</i> , 2022, 25, 105380.	1.9	2
754	Demographic, behavioural and occupational risk factors associated with SARS-CoV-2 infection in UK healthcare workers: a retrospective observational study. <i>BMJ Open</i> , 2022, 12, e063159.	0.8	3
755	Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS. <i>Journal of Proteome Research</i> , 0, , .	1.8	2
756	Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	4
757	Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e944-e955.	3.4	34
759	Clinical and immune response characteristics among vaccinated persons infected with SARS-CoV-2 delta variant: a retrospective study. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 899-914.	1.3	2
760	Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211418.	1.0	4

#	ARTICLE	IF	CITATIONS
761	COVID-19 vaccines: Update of the vaccines in use and under development. <i>Vacunas (English Edition)</i> , 2022, 23, S88-S102.	0.3	0
762	Mapping the Arab genome. <i>Nature Genetics</i> , 2022, 54, 1761-1763.	9.4	3
764	Efficacy and Safety of COVID-19 Vaccines – An Update. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 112.	1.0	11
765	Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. <i>Journal of Infectious Diseases</i> , 0, .	1.9	2
766	BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children. <i>Npj Vaccines</i> , 2022, 7, .	2.9	5
768	Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. <i>Science Immunology</i> , 2023, 8, .	5.6	89
769	Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. <i>Plasmonics</i> , 2023, 18, 311-347.	1.8	4
771	International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic. <i>Lancet Oncology</i> , The, 2022, 23, e544-e551.	5.1	6
772	Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters. <i>Vaccines</i> , 2023, 11, 12.	2.1	1
773	Vax the Max, a Gamification Intervention for COVID-19 Vaccination Task Engagement in the Inpatient Setting. <i>American Journal of Medical Quality</i> , 2023, 38, 47-56.	0.2	3
774	Production of a Monoclonal Antibody to the Nucleocapsid Protein of SARS-CoV-2 and Its Application to ELISA-Based Detection Methods with Broad Specificity by Combined Use of Detector Antibodies. <i>Viruses</i> , 2023, 15, 28.	1.5	5
775	Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants. <i>Vaccines</i> , 2022, 10, 2110.	2.1	2
776	Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. <i>International Journal of Infectious Diseases</i> , 2023, 128, 212-222.	1.5	9
777	Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. <i>IScience</i> , 2022, 25, 105649.	1.9	7
778	Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 32, 100660.	1.3	9
779	Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. <i>Journal of Infection and Public Health</i> , 2023, 16, 250-256.	1.9	10
780	A genetically engineered, stem-cell-derived cellular vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100843.	3.3	0
781	Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5

#	ARTICLE	IF	CITATIONS
782	An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight. <i>Molecules</i> , 2023, 28, 795.	1.7	8
783	Effects of Second Dose of SARS-CoV-2 Vaccination on Household Transmission, England. <i>Emerging Infectious Diseases</i> , 2023, 29, 127-132.	2.0	5
784	COVID-19 Health Passes: Practical and Ethical Issues. <i>Journal of Bioethical Inquiry</i> , 2023, 20, 125-138.	0.9	3
785	Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar. <i>Nature Communications</i> , 2023, 14, .	5.8	4
786	SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	160
787	COVID-19 Vaccinesâ€”All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
788	COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte. <i>Journal of Infection and Public Health</i> , 2023, 16, 233-249.	1.9	7
789	SARS-CoV-2 Infection in Winter 2021/2022: The Association of Varying Clinical Manifestations With and Without Prior Vaccination. <i>Cureus</i> , 2022, , .	0.2	0
790	Effectiveness of Messenger RNA Vaccines against SARS-CoV-2 Infection in Hemodialysis Patients: A Caseâ€”Control Study. <i>Vaccines</i> , 2023, 11, 49.	2.1	2
791	Propagation of SARS-CoV-2 in a Closed Cell Culture Device: Potential GMP Compatible Production Platform for Live-Attenuated Vaccine Candidates under BSL-3 Conditions?. <i>Viruses</i> , 2023, 15, 397.	1.5	0
792	Covid-19 Vaccine Efficacy: Accuracy Assessment, Comparison, and Caveats. <i>Journal of Data Science</i> , 2024, , 45-55.	0.5	0
793	Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RABD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus. <i>Heliyon</i> , 2023, 9, e15032.	1.4	0
794	Development and applications of mRNA treatment based on lipid nanoparticles. <i>Biotechnology Advances</i> , 2023, 65, 108130.	6.0	10
795	mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	5
796	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
797	Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data. <i>International Journal of Infectious Diseases</i> , 2023, 129, 188-196.	1.5	10
798	Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
799	Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 3703.	1.2	2

#	ARTICLE	IF	CITATIONS
800	A Synthetic Biology Approach for Vaccine Candidate Design against Delta Strain of SARS-CoV-2 Revealed Disruption of Favored Codon Pair as a Better Strategy over Using Rare Codons. <i>Vaccines</i> , 2023, 11, 487.	2.1	6
801	Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants. <i>Obstetrics and Gynecology Clinics of North America</i> , 2023, 50, 279-297.	0.7	13
802	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
803	Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	0
804	SARS-CoV-2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control. <i>EFSA Journal</i> , 2023, 21, .	0.9	16
805	Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents. <i>Journal of Pediatrics</i> , 2023, 257, 113371.	0.9	4
806	Effectiveness of mRNA and viral vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
807	An update on SARS-CoV-2 immunization and future directions. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
808	The impact of influenza vaccination on surgical outcomes in COVID-19 positive patients: An analysis of 43,580 patients. <i>PLoS ONE</i> , 2023, 18, e0281990.	1.1	0
809	Comparative Performance Evaluation of Personal Protective Measures and Antiviral Agents Against SARS-CoV-2 Variants: A Narrative Review. <i>BMC Clinical Pathology</i> , 2023, 16, 2632010X2311612.	0.7	3
810	Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	17
811	Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
812	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
813	SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic. <i>Vaccines</i> , 2023, 11, 682.	2.1	7
814	Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	12
815	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. <i>Viruses</i> , 2023, 15, 856.	1.5	10
816	Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study. <i>Vaccine</i> , 2023, 41, 3556-3563.	1.7	7
817	Vaccine politics: Law and inequality in the pandemic response to COVID-19. <i>Global Policy</i> , 2023, 14, 229-246.	1.0	6

#	ARTICLE	IF	CITATIONS
818	A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB. <i>Vaccines</i> , 2023, 11, 778.	2.1	1
819	Immunology of COVID-19. , 2024, , 52-71.		0
820	Vaccine Basics and the Development and Rollout of COVID-19 Vaccines. , 2024, , 326-348.		0
821	COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies. <i>MedComm</i> , 2023, 4, .	3.1	19
822	Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	3
823	COVID-19 Anti-Vaccine Sentiments in Malaysia: Narratives of Comments from Facebook Post. <i>Vaccines</i> , 2023, 11, 834.	2.1	0